5,830 Shares in Hologic, Inc. (NASDAQ:HOLX) Acquired by GF Fund Management CO. LTD.

GF Fund Management CO. LTD. bought a new position in Hologic, Inc. (NASDAQ:HOLX) in the fourth quarter, Holdings Channel reports. The firm bought 5,830 shares of the medical equipment provider’s stock, valued at approximately $420,000.

A number of other institutional investors also recently bought and sold shares of the stock. Venturi Wealth Management LLC lifted its stake in Hologic by 156.3% during the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock valued at $31,000 after acquiring an additional 261 shares during the period. EverSource Wealth Advisors LLC lifted its stake in Hologic by 79.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock valued at $42,000 after acquiring an additional 260 shares during the period. Smartleaf Asset Management LLC lifted its stake in Hologic by 36.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock valued at $43,000 after acquiring an additional 159 shares during the period. Smithfield Trust Co lifted its stake in Hologic by 160.0% during the 4th quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider’s stock valued at $45,000 after acquiring an additional 400 shares during the period. Finally, Raiffeisen Bank International AG acquired a new stake in Hologic during the 4th quarter valued at approximately $49,000. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have commented on HOLX. Raymond James restated an “outperform” rating and set a $71.00 price objective (down from $90.00) on shares of Hologic in a research note on Friday, May 2nd. Wall Street Zen cut shares of Hologic from a “buy” rating to a “hold” rating in a research note on Monday, May 5th. Citigroup decreased their price objective on shares of Hologic from $80.00 to $70.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. William Blair restated an “outperform” rating on shares of Hologic in a research note on Thursday, February 6th. Finally, Leerink Partners cut shares of Hologic from an “outperform” rating to a “market perform” rating and decreased their target price for the company from $80.00 to $75.00 in a research note on Thursday, February 6th. Twelve equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $77.42.

Hologic Stock Performance

HOLX opened at $54.28 on Monday. The stock has a market cap of $12.10 billion, a P/E ratio of 17.12, a P/E/G ratio of 2.14 and a beta of 0.54. The firm has a fifty day moving average price of $58.17 and a 200 day moving average price of $66.43. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. Hologic, Inc. has a 1 year low of $51.90 and a 1 year high of $84.67.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, topping the consensus estimate of $1.02 by $0.01. The company had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1 billion. Hologic had a net margin of 18.42% and a return on equity of 19.72%. The firm’s revenue was down 1.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.03 EPS. Equities research analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Martin D. Madaus purchased 5,445 shares of the business’s stock in a transaction that occurred on Wednesday, May 7th. The stock was bought at an average price of $55.24 per share, with a total value of $300,781.80. Following the acquisition, the director now owns 5,445 shares in the company, valued at $300,781.80. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.88% of the stock is owned by insiders.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.